Funds from the round will be used to support ongoing development of applications for the Hayward, Calif.-based company’s Nano-Pulse Stimulation technology.
The Nano-Pulse Stimulation system is a novel, non-thermal tech platform designed to deliver nanosecond duration energy pulses intended to disrupt functions of internal cell structures while maintaining outer cell membranes, Pulse Biosciences said.
The rights offering, which will be made through distributing non-transferable subscription rights to purchase the company’s common stock, will include an over-subscription privilege to purchase additional shares that are unsubscribed at the end of the offering, according to an SEC filing.
Board chair Robert Duggan indicated that he plans to exercise all of his basic subscription rights in an amount not less than $15.6 million, according to the filing. Pulse Biosciences has not yet priced or set a date on the rights offering.
Earlier this month, Pulse Biosciences launched a clinical feasibility study of its Nano-Pulse Stimulation platform intended to treat cutaneous warts.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.